Phase 2 × Terminated × Urinary Bladder Neoplasms × Clear all NeuroPrevPTSD
Phase 2 Terminated
19 enrolled
Surgery With or Without Postoperative Intensity Modulated Radiation Therapy in Treating Patients With Urothelial Bladder Cancer
Phase 2 Terminated
14 enrolled 16 charts
Avelumab and Radiation in Muscle-Invasive Bladder Cancer
Phase 2 Terminated
14 enrolled 14 charts
Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors
Phase 2 Terminated
23 enrolled 15 charts
PRESERVE3
Phase 2 Terminated
92 enrolled 24 charts
STARBURST
Phase 2 Terminated
11 enrolled
Afatinib in Advanced Refractory Urothelial Cancer
Phase 2 Terminated
32 enrolled 14 charts
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors
Phase 2 Terminated
54 enrolled 11 charts
Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy (SWOG GAP TRIAL)
Phase 2 Terminated
6 enrolled 12 charts
To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Participants With Advanced Non-small Cell Lung Cancer
Phase 2 Terminated
26 enrolled 18 charts
A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)
Phase 2 Terminated
61 enrolled 26 charts
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
Phase 2 Terminated
4 enrolled 9 charts
Nab-paclitaxel Plus Gemcitabine as First-line Therapy for Cisplatin-ineligible or Cisplatin-incurable Advanced Urothelial Carcinoma
Phase 2 Terminated
3 enrolled 9 charts
First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma
Phase 2 Terminated
36 enrolled 14 charts
LODESTAR
Phase 2 Terminated
83 enrolled 16 charts
Sacral Nerve Stimulation in Treating Low Anterior Resection Syndrome or Fecal Incontinence in Patients With Locally Advanced Rectal Cancer or Other Pelvic Cancer, the RESTORE Study
Phase 2 Terminated
3 enrolled 5 charts
ATLAS
Phase 2 Terminated
97 enrolled 12 charts
CheckMate 9UT
Phase 2 Terminated
142 enrolled 20 charts
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Phase 2 Terminated
8 enrolled 16 charts
Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder
Phase 2 Terminated
17 enrolled 9 charts
Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression
Phase 2 Terminated
13 enrolled 8 charts
GCISAVE
Phase 2 Terminated
65 enrolled
Prevention and Management of Intravesical BCG-related Lower Urinary Tract Symptoms
Phase 2 Terminated
3 enrolled
Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma
Phase 2 Terminated
6 enrolled
Neoadjuvant Durvalumab Alone Versus Durvalumab With Olaparib in Patients Ineligible for Cisplatin With Muscle-Invasive Urothelial Carcinoma of the Bladder Followed by Radical Cystectomy
Phase 2 Terminated
140 enrolled
Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery
Phase 2 Terminated
50 enrolled 27 charts
A Study of the CDX-1307 Vaccine Regimen in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer (The "N-ABLE" Study)
Phase 2 Terminated
3 enrolled
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
Phase 2 Terminated
4 enrolled 8 charts
Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer
Phase 2 Terminated
32 enrolled 6 charts
Sunitinib Malate in Treating Patients With Recurrent Transitional Cell Bladder Cancer
Phase 2 Terminated
19 enrolled 11 charts
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
Phase 2 Terminated
3 enrolled 9 charts
Gemcitabine and Irinotecan in Treating Patients With Locally Advanced or Metastatic Bladder Cancer
Phase 2 Terminated
16 enrolled 4 charts
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Phase 2 Terminated
22 enrolled 12 charts
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Phase 2 Terminated
2 enrolled 9 charts
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
Phase 2 Terminated
7 enrolled 5 charts
DN24-02 as Adjuvant Therapy in Subjects With High Risk HER2+ Urothelial Carcinoma
Phase 2 Terminated
142 enrolled 13 charts
Neoadjuvant Gemcitabine and Fractionated, Weekly Cisplatin For Muscle Invasive Bladder Cancer and Patients Not Candidates For High Dose Cisplatin
Phase 2 Terminated
2 enrolled 8 charts
S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract
Phase 2 Terminated
65 enrolled 14 charts
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Phase 2 Terminated
1 enrolled 5 charts
Study of Gemcitabine, Carboplatin, and Panitumumab (GCaP) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Phase 2 Terminated
4 enrolled 6 charts
Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Phase 2 Terminated
2 enrolled 5 charts
Iressa and Taxotere Study in Patients With Metastatic Urothelial Cancer
Phase 2 Terminated
50 enrolled 5 charts
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
Phase 2 Terminated
41 enrolled
Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer
Phase 2 Terminated
16 enrolled 11 charts
PURO
Phase 2 Terminated
2 enrolled
RAD001
Phase 2 Terminated
28 enrolled
Trial of Maintenance SUO11248 Versus Placebo Post Chemotherapy for Patients With Advanced Urothelial Carcinoma
Phase 2 Terminated
54 enrolled 9 charts
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Phase 2 Terminated
27 enrolled 8 charts
S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
Phase 2 Terminated
6 enrolled
Detection of Bladder Tumors After 30 Min Instillation of Hexvix
Phase 2 Terminated
38 enrolled